Cholesterol unlocks clues to prostate cancer spread

(Medical Xpress)—The findings could help explain why taking statins – commonly used cholesterol-lowering drugs – is thought to slow the progress of the disease in some cases.

The scientists, from The University of Manchester, made the discovery by combining in the lab with arachidonic acid (AA), an omega-6 fatty acid that has been shown to attract prostate cancer cells to the bone marrow, where it is found naturally in high concentrations.

When the prostate cancer cells were exposed to AA the researchers found that they changed shape, becoming rounder and also sprouting projections that helped them to squeeze through the gaps in the surrounding tissues and become established in the bone marrow.

But the researchers found they were able to stop the cells developing these characteristics by treating them with statins, which disrupt their ability to manufacture cholesterol.

Professor Noel Clarke, who jointly led the study with Dr Mick Brown and Dr Thomas Tawadros at The University of Manchester, said: "Our study shows how naturally occurring fatty acids in the directly interact with the body's system of manufacturing cholesterol to enhance prostate ' ability to spread around the body. Understanding this process will provide vital clues as to how drugs like might benefit certain groups of prostate cancer patients who are more at risk of their cancer spreading."

The University of Manchester is part of Manchester Cancer Research Centre a three-way partnership also including Cancer Research UK and The Christie NHS Foundation Trust.

Nell Barrie, senior science information manager at Cancer Research UK, said: "Prostate cancer spreading to the bones is a major challenge for doctors and unfortunately it's very difficult to treat. Altering cholesterol metabolism or blocking the ways in which cells are able to change their shape, and thereby their ability to spread, could lead to major advances in treating men with aggressive forms of the disease."

"Finding ways to better treat cancer by taking research from the lab to help patients is at the heart of the new Manchester Cancer Research Centre – set to open this autumn."

More information: Brown, M et al 'Arachidonic acid induction of Rho mediated transendothelial migration in prostate cancer' British Journal of Cancer DOI: 10.1038/bjc. 2014.99

add to favorites email to friend print save as pdf

Related Stories

Prostate cancer prognosis hope

Oct 29, 2012

Cancer of the prostate – the most common male cancer in the UK – presents in two distinct ways: a low-risk type, which may never cause any symptoms, and a high-risk form that needs treatment to prevent it spreading to ...

Recommended for you

Better classification to improve treatments for breast cancer

11 hours ago

Breast cancer can be classified into ten different subtypes, and scientists have developed a tool to identify which is which. The research, published in the journal Genome Biology, could improve treatments and targeting of tre ...

Risk of diabetes up in hodgkin's lymphoma survivors

13 hours ago

(HealthDay)—Para-aortic radiation correlates with increased diabetes mellitus (DM) risk for Hodgkin's lymphoma (HL) survivors, according to a study published online Aug. 25 in the Journal of Clinical On ...

User comments